Greenwich Lifesciences Inc
(GLSI)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2024 | 12-2023 | 12-2022 | 12-2021 | 12-2020 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -15,789 | -8,892 | -7,825 | -4,571 | -1,863 |
| Depreciation Amortization | 4 | 4 | 4 | 4 | 4 |
| Accounts payable and accrued liabilities | 921 | 36 | N/A | -527 | -93 |
| Other Working Capital | 1,265 | 32 | -122 | -385 | 28 |
| Other Operating Activity | 6,332 | 2,343 | 1,744 | 1,187 | 771 |
| Operating Cash Flow | $-7,267 | $-6,479 | $-6,200 | $-4,292 | $-1,153 |
| Cash Flows From Investing Activities | |||||
| Investing Cash Flow | $N/A | $N/A | $N/A | $N/A | $N/A |
| Cash Flows From Financing Activities | |||||
| Debt Issued | N/A | N/A | N/A | -275 | N/A |
| Debt Repayment | N/A | N/A | N/A | N/A | -360 |
| Common Stock Issued | 4,369 | N/A | N/A | 3,111 | 30,167 |
| Common Stock Repurchased | N/A | N/A | -7,536 | N/A | N/A |
| Financing Cash Flow | $4,369 | $N/A | $-7,536 | $2,835 | $29,807 |
| Beginning Cash Position | 6,989 | 13,468 | 27,204 | 28,660 | 7 |
| End Cash Position | 4,092 | 6,989 | 13,468 | 27,204 | 28,660 |
| Net Cash Flow | $-2,897 | $-6,479 | $-13,736 | $-1,456 | $28,654 |
| Free Cash Flow | |||||
| Operating Cash Flow | -7,267 | -6,479 | -6,200 | -4,292 | -1,153 |
| Free Cash Flow | -7,267 | -6,479 | -6,200 | -4,292 | -1,153 |